Рибосомальная иммуностимуляция. Обзор исследований, оценивающих ее клиническую значимость в предотвращении инфекций верхних и нижних дыхательных путей у взрослых и детей

1. Paradise J.L., Rockette H.E., Colburn D.K., et al. Otitis media in 2253 Pittsburgh-area infants: prevalence and risk factors during the first two years of life. Pediatrics 1997; 99 (3): 318–333.

2. Wald E.R., Guerra N., Byers C. Upper respiratory tract infections in young children: duration of and frequency of complications. Pediatrics 1991; 87 (2): 129–133.

3. Teele D.W., Klein J.O., Rosner B. et al. Epidemiology of otitis media during the first seven years of life in children in greater Boston: a prospective, cohort study. J. Infect. Dis. 1989; 160 (1): 83–94.

4. International Consensus Report on the diagnosis and management of rhinitis: International Rhinitis Management Working Group. Allergy 1994; 49 (suppl. 19): 1–34.

5. Falcoff H., Francois M., de Saint-Hardouin G., et al. Dixieme conference de consensus en therapeutique antiinfectieuse, 19 Juin 1996: les infections ORL. Med. Mal. Infect. 1997; 27: 334–388.

6. Current estimates from the National Health Interview Survey (1993): Vital and health statistics; US Department of Health and Human Services. Public Health Service; 1994.

7. Graham M.H. The epidemiology of acute respiratory infections in children and adults: a global perspective. Epidemiol. Rev. 1990; 120: 149–178.

8. Wald E.R. Sinusitis in infants and children. Ann. Otol. St. Louis 1992; suppl. 155: 37–41.

9. Bellanti J.A. Recurrent respiratory tract infections in paediatric patients. Drugs 1997; 54 (suppl. 1): 1–4.

10. McCutcheon H., Fitzgerald M. The public health problem of acute respiratory illness in childcare. J. Clin. Nurs. 2001; 10 (3): 305–310.

11. Le Fur P., Sermet C. Rhinopharyngites et antibiotherapie en 1992: rapport CREDES n° 1105. Paris; 1995.

12. Garabedian E.N., Dubreuil C., Triglia J.C. Effectiveness and tolerance of Ribomunyl® tablets in preventing middle ear infections in children affected by S.O.M. [poster and abstract]. Jn: International congress on prevention of infection, 1990 June, Nice. Nice; 1990. 21.

13. Anthonisen N.R. 0M-8BV for COPD. Am. J. Respir. Crit. Care Med. 1997; 156 (6): 1713–1714.

14. Heikkinen T., Ruuskanen O., Ziegler T. et al. Short-term use of amoxicillin-clavulanate during uoper respiratory tract infection for prevention of acute otitis media. J. Pediatr. 1995; 126 (2): 313–316.

15. Autret E., Ployet M.J. Le rapport benefice/risque de l, antibiotherapie des rhinopharyngites de l'enfant. In: Gehanno P., Leophonte P., Mouton Y. eds. La colonisation microbienne des voies respiratoires. Paris: John Libbey Eurotext; 1995. 209–213.

16. Todd J.K., Todd N., Damato J. et al. Bacteriology and treatment of purulent nasopharyngitis: a double blind, placebocontrolled evaluation. Pediatr. Infect. Dis. 1984; 3 (3): 226–232.

17. Garabedian E.N., Bellity A., Tashjian G. et al. Etat de la resistance du pneumocoque a la penicilline dans le cadre de l'epidemiologie bacterienne actuelle de l'otite moyenne aigue de l'enfant. Med. Mal. Infect. 1994; 24: 674–680.

18. Geslin P., Fremaux A., Sissia G. Evolution de la resistance aux betalactamines des pneumocoques isoles d'otites moyennes aigues de l'enfant en France depuis 1987: bilan du Centre National de Reference. Lettre Infectiol. 1994; 9: 4–10

19. Collet J.P., Shapiro P., Ernst P., et al. Effect of an immunostimulating agent on acute exacerbations and hospitalizations in patients with chronic obstructive pulmonary disease: the PARI-IS Study Steering Committee and Research Group. Prevention of acute respiratory infection by an immunostimulant. Am. J. Respir. Crit. Care Med. 1997; 156 (6): 1719–1724.

20. Centanni S., Allegra L. Influenza in patients with chronic respiratory diseases: a comparison between two prophylactic regimens in elderly patients. J. Chemother. 1997; 9 (4): 273–278.

21. Serrano E., Demanez J.P., Morgon A. et al. Effectiveness of ribosomal fractions of Klebsiella pneumoniae, Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae and the membrane fraction of Kp (Ribomunyl®) in the prevention of clinical recurrences of infectious rhinitis: results of a multicenter double-blind placebo-controlled study. Eur. Arch. Otorhinolaryngol. 1997; 254 (8): 372–375.

22. Vautel J.M., Cauquil J., Perruchet A.M. et al. Prevention of recurrent ear, nose and throat infections in young children with Ribomunyl®: double-blind, placebo-controlled study. Curr. Ther. Res. 1993; 53: 722–729.

23. Collet J.P., Floret D., Ducruet T. et al. Therapeutic efficacy of Imocur in reducing recurrent respiratory infections in children attending day care centers [abstract]. Jn: Presented at the European Respiratory Disease Society; 1991 Sept. Brussels. Brussels;1991. 54.

24. Clot J. Pharmacology of ribosomal immunotherapy. Drugs 1997; 54 (suppl. 1): 33–36.

25. Youmans A.S., Youmans G.P. Immunogenic activity of a ribosomal fraction obtained from Mycobacterium tuberculosis. J. Bacteriol. 1965; 89: 1291–1298.

26. Nikolaeva L.V., Savel'ev E.P. Molecular-biological and immunological properties of ribosomal vaccines. Biomed. Sci. 1991; 2 (1): 1–10.

27. Levenson V.J., Mallett C.P., Hale T.L. Protection against local Shigella sonnei infection in mice by parenteral immunization with a nucleoprotein subcellular vaccine. Infect. and Immun. 1995; 63 (7): 2762–2765.

28. Faure G.C., Bene M.C., Simon C. et al. Increase in specific antibody-forming cells in human tonsils after oral stimulation with D-53, a ribosomal vaccine. Int. J. Immunopharmacol. 1990; 12 (3): 315–320.

29. Zanin C., Perrin P., Bene M.C. et al. Antibody-producing cells in peripheral blood and tonsils after oral treatment of children with bacterial ribosomes. Int. J. Immunopharmacol. 1994; 16 (7): 497–505.

30. Kolopp-Sarda M.N., Bene M.C., Allaire J.M. et al. Kinetics of specific salivary IgA responses in man after oral challenge by ribosomal immunostimulant. Int. J. Immunopharmacol. 1997; 19 (3): 181–186.

31. Caliot E., Libon C., Kerneis S. et al. Translocation of ribosomal immunostimulant through an in vitro-reconstituted digestive barrier containing M-like cells. Scand. J. Immunol. 2000; 52 (6): 588–594.

32. Lafont S., Millet I., Kouassi E. et al. Induction of murine В cell proliferation and immunoglobulin synthesis by some bacterial ribosomes. Microbiol. and Immunol. 1988; 32 (10): 1043–1058.

33. Maccario R., De Amici M., Montagna D. et al. Evaluation of immune response of Waldeyer's tissues after local stimulation with bacterial ribosomal extracts: B, T and NK lymphocyte phenotype and function. Adv. Otorhinolaryngol. 1992; 47: 332–337.

34. Millet I., Lafont S., Jeannin M., et al. Proliferative response of human T lymphocytes to a vaccinal preparation of ribosomes from Streptococcus pyogenes. Int. Arch. Allergy Appl. Immunol. 1988; 86 (4): 432–435.

35. Roques C., Frayret M.N., Luc J. et al. Effect of an in vivo immunostimulant treatment on PMN functions: interactions with antibiotics in vitro. Int. J. Immunopharmacol. 1991; 13 (8): 1051–1057.

36. Roques C., Frayret M.N., Luc J. et al. Immunostimulant effects on granulocyte functions during an acute respiratory infection. Dev. Biol. Stand. 1992; 77: 183–187.

37. Kantar A., Oggiano N., Romagnoni G.G. et al. Effect of oral administration of bacterial extracts on the bactericidal capacity of polymorphonuclear leucocytes in children with recurrent respiratory infections. J. Int. Med. Res. 1991; 19 (6): 451–456.

38. Hbabi L., Roques C., Michel G. et al. In vitro stimulation of polymorphonuclear cell adhesion by Ribomunyl® and antibiotic plus Ribomunyl® combinations: effects on CD 18, CD35 and CD 16 expression. Int. J. Immunopharmacol. 1993; 15 (12): 163–173.

39. Hbabi-Haddioui L., Roques C. Inhibition of Streptococcus pneumoniae adhesion by spcific salivary IgA after oral immunisation with a ribosomal immunostimulant. Drugs 1997; 54 (suppl. 1): 29–32.

40. Balbi B., Aufiero A., Pesci A. et al. Lower respiratory tract inflammation in chronic bronchitis: evaluation by bronchoalveolar lavage and changes associated with treatment with Immucytal, a biological response modifier. Chest 1994; 106 (3): 819–826.

41. Pujol J.L., Klein B., Godard P. et al. Bacterial ribosomal immunostimulants prime alveolar macrophages in vivo to produce interleukin 1 in vitro. Chest 1991; 100 (3): 644–645.

42. Sironi M., Sica A., Riganti F. et al. Interleukin-6 gene expression and production induced in human monocytes by membrane proteoglycans from Klebsiella pneumoniae. Int. J. Immunopharmacol. 1990; 12 (4): 397–402.

43. Luini W., De Rossi M., Licciardello L. et al. Chemotactic cytokine gene expression and production induced in human monocytes by membrane proteoglycans from Klebsiella pneumoniae. Int. J. Immunopharmacol. 1991; 13 (6): 631–637.

44. Allavena P., Erroi A., Pirelli A. et al. Stimulation of cytotoxic and non-cytotoxic functions of natural killer cells by bacterial membrane proteoglycans and ribosomes. Int. J. Immunopharmacol. 1989; 11 (1): 29–34.

45. Lacomme Y., Narcy P. Prevention par immunotherapie ribosomale des episodes de surinfection recidivante de la sphere O.R.L. chez l'enfant: resultats cliniques d'une etude multicentrique. Immunol. Med. 1985; 11: 73–75.

46. Haguenauer J.P. Prevention des episodes infectieux recidivants de la sphere O.R.L. par Ribomunyl® comprimes chez l'enfant de moins de 5 ans. Immunologie Med. 1987; 18: 36–39.

47. Elies W., Pletan Y. An international medico-economic survey of 2007 children with recurrent nasopharyngitis and acute otitis media. Drugs 1997; 54 (suppl. 1): 5–12.

48. Paradise J.L. On classifying otitis media as suppurative or nonsuppurative, with a suggested clinical schema. J. Pediatr. 1987; 111 (6, pt 1): 948–951.

49. Periodic safety update report. France: Laboratoires Pierre Fabre SA. (Data on file).

50. Boyle P., Bellanti J.A., Robertson С. Meta-analysis of published clinical trials of a ribosomal vaccine (Ribomunyl®) in prevention of respiratory infections. Bio-Drugs 2000; 14 (6): 389–408.

51. Perruchet A.M. Bilan epidemiologique de l'otite seromuqueuse chez 458 ORL francais. Rev. Soc. Fr. ORL 1991; 7: 59–62.

52. Banz K., Schwicker D., Thomas A.M. Economic evaluation of immunoprophylaxis in children with recurrent ear, nose and throat infections. Pharmacoeconomics 1994; 6 (5): 464–477.

53. Schwarz B., Dangl-Neugaard B. An economic analysis using ribosomal immunotherapy to treat children with recurrent upper respiratory tract infections. Clin. Drug Invest. 1997; 14 (3): 206–210.

54. Banz K., Thomas A.M., Olivieri D. Economic evaluation of ribosomal immunotherapy in patients with chronic ear, nose and throat and respiratory tract infections: results for Italy. Bio-Drugs 1998; 10 (5): 385–396.